BioAge Labs news

The company achieved a key clinical milestone by dosing the first participant in its Phase 2 QUELL-CV trial for BGE-102, demonstrating progress in its pipeline. Previous Phase 1 data showed a well-tolerated profile with potential best-in-class inflammatory biomarker reductions. Upcoming topline data in H2 2026 and continued investor engagement suggest positive momentum in clinical development.

Company achieved significant clinical milestones with first participant dosed in Phase 2 QUELL-CV trial, demonstrated strong Phase 1 efficacy data (98% IL-1β suppression, 86% hsCRP reduction), announced expansion into new indication (diabetic macular edema), maintains strong cash position ($381.3M sufficient through 2029), and continues advancing pipeline programs including APJ agonists and strategic partnerships with Novartis and Lilly.

The company announced successful progression to Phase 2 trials with strong Phase 1 data showing potential best-in-class hsCRP reductions (86% median reduction), good tolerability profile, and expansion into additional indications (diabetic macular edema). The advancement of lead candidate BGE-102 with promising efficacy and safety data supports positive momentum for the company's pipeline and clinical development strategy.

The company reported strong Phase 1 efficacy data with ≥85% median hsCRP reductions at both tested doses, excellent safety profile with no serious adverse events, and clear advancement to Phase 2 trials in multiple indications. The results position BGE-102 as a potential best-in-class therapy with broad market potential in cardiovascular and retinal diseases.

Phase 1 results for BGE-102 demonstrated best-in-class inflammatory biomarker reductions with favorable tolerability; Phase 2 trial planned for H1 2026 with data expected H2 2026.